Millions of Americans are losing weight on GLP-1 drugs. A study presented June 14, 2026, at the Endocrine Society's ENDO 2026 meeting in Chicago has surfaced a concerning behavioral pattern: people on these medications are also moving significantly less.
Using Fitbit activity data linked to electronic health records from NIH's All of Us Research Program, the study found that adults with obesity who began GLP-1 therapy saw daily steps drop by 560 and moderate-to-vigorous physical activity (MVPA) decline by nearly 6 minutes per day — statistically significant changes that occurred alongside, not instead of, successful weight loss.
